Androgen Receptor (AR) positivity definitions -Phase I: Metastatic or unresectable AR+
        triple-negative breast cancer (TNBC); AR positivity defined as IHC staining of >0% of tumor
        nuclei.

        OR

        -Phase II: Metastatic or unresectable AR+ triple-negative breast cancer (TNBC); AR
        positivity defined as IHC staining of ≥10% of tumor nuclei.

        Inclusion Criteria for Phase I and II study.

        In addition to being AR positive as defined in protocol, subjects must also meet all of the
        following applicable inclusion criteria.

          -  Histological or cytological confirmed, metastatic or unresectable triple-negative
             breast cancer (TNBC). TNBC will be defined as expression of ER<10%, PR< 10% and HER2
             negative either by IHC (0, 1+ are negative, 2+ equivocal) or in situ hybridization
             method (ratio <2.0 is negative).

          -  Written informed consent and HIPAA authorization for release of personal health
             information. NOTE: HIPAA authorization may be included in the informed consent or
             obtained separately.

          -  Up to 1 prior line of systemic therapy for metastatic disease is allowed. Combination
             therapy will be considered 1 line.

          -  Age ≥ 18 years at the time of consent.

          -  ECOG Performance Status of 0 or 1 within 28 days prior to registration.

          -  Life expectancy of > 12 weeks as determined by the treating physician.

          -  Measurable disease according to RECIST 1.1 within 28 days prior to registration.

          -  No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS
             involvement must meet ALL of the following to be eligible:

               -  At least 28 days from prior definitive treatment of their CNS disease by surgical
                  resection, stereotactic body radiation therapy (SBRT) or whole brain radiation
                  treatment (WBRT) at the time of registration

               -  AND asymptomatic and off systemic corticosteroids and/or enzyme-inducing
                  anti-epileptic medications for brain metastases for >14 days prior to
                  registration.

          -  Prior cancer treatment must be completed at least 14 days prior to registration and
             the subject must have recovered from all reversible acute toxic effects of the regimen
             (other than alopecia) to ≤grade 1 or to baseline prior to initiation of that therapy.

          -  Screening rate-corrected QT interval (QTc) must be <450msec and a resting heart rate
             of at least 50-90 bpm via a standard 12-lead ECG within 28 days prior to registration.

          -  Demonstrate adequate bone marrow and organ function as defined in the protocol; all
             screening labs to be obtained within 28 days prior to registration.

          -  Females of childbearing potential must have a negative serum pregnancy test within 7
             days prior to registration. NOTE: Females are considered of child bearing potential
             unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal
             ligation, or bilateral oophorectomy), or they are naturally postmenopausal for at
             least 12 consecutive months, or her male partner has had a vasectomy at least 6 months
             prior to screening (The sterilized male partner must be her only sexual partner.).

          -  Females of childbearing potential and males must be willing to abstain from
             heterosexual activity or must agree to use adequate contraception (hormonal or barrier
             method) for the duration of study participation and for 3 weeks after discontinuation
             of study treatment.

          -  As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures for the entire length of the study.

          -  Able to swallow bicalutamide and ribociclib capsules/tablets.

        Exclusion Criteria:

          -  Prior therapy with AR antagonists including but not limited to bicalutamide,
             enzalutamide, abiraterone and orteronel.

          -  Prior therapy with any CDK 4/6 inhibitors with the exception of participation in a
             window or preoperative study for Stage I-III operable breast cancer..

          -  Active infection requiring systemic therapy.

          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study).

          -  Known additional malignancy that is active and/or progressive requiring treatment;
             exceptions include basal cell or squamous cell skin cancer, in situ cervical or
             bladder cancer, or other cancer for which the subject has been disease-free for at
             least three years.

          -  Treatment with any investigational drug within 14 days prior to registration or within
             5 half-lives of the investigational product, whichever is longer. Immunotherapies such
             as PD-L1 or PD-1 inhibitors only require a 14 day window, regardless of half-life.

          -  Subject who has received radiotherapy <14 days prior to registration, and who has not
             recovered to grade 1 or better from related side effects of such therapy (exceptions
             include alopecia and any adverse events deemed by the investigator to be unlikely to
             interfere with the study drug safety).

          -  Subject has had major surgery within 14 days prior to registration or has not
             recovered from major side effects of the surgery (tumor biopsy is not considered as
             major surgery).

          -  Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.

          -  Any impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled
             nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

          -  Known history of HIV infection (testing not mandatory).

          -  Any concurrent severe and/or uncontrolled medical condition that would, in the
             investigator's judgment, cause unacceptable safety risks, contraindicate subject
             participation in the clinical study or compromise compliance with the protocol (e.g.
             chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled
             fungal, bacterial or viral infections, etc.).

          -  Subjects with any of the following conditions are excluded:

               -  Serious or non-healing wound, ulcer, or bone fracture.

               -  History of abdominal fistula, gastrointestinal perforation, or intra- abdominal
                  abscess within 28 days prior to registration.

               -  Any history of cerebrovascular accident (CVA) or transient ischemic attack within
                  12 months prior to registration.

               -  Any history of arterial or venous thrombosis/thromboembolic event, including
                  pulmonary embolism within the past 12 months prior to registration.

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or
                  symptomatic pericarditis within 6 months prior to registration.

               -  Symptomatic congestive heart failure (New York Heart Association III-IV) or
                  documented current cardiomyopathy with left ventricular ejection fraction (LVEF)
                  <50%

               -  Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia) or
                  clinically significant, complete left bundle branch block, high-grade AV block
                  (e.g. bifascicular block, Mobitz type II and third-degree AV block).

               -  Any episode of atrial fibrillation in the prior 12 months.

               -  Long QT syndrome or family history of idiopathic sudden death or congenital long
                  QT syndrome.

               -  Concomitant use of medication(s) with a known risk to prolong the QT interval
                  and/or known to cause Torsades de Pointe that cannot be discontinued (within 5
                  half-lives or 7 days prior to starting study drug) or replaced by safe
                  alternative medication. See ManualDocuments/Info tab of the EDC for list of
                  medications.

               -  Systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening.

          -  Currently receiving any known strong inducers or inhibitors of CYP3A4/5 which cannot
             be discontinued 7 days prior to starting study drug (see Appendix 1 for details).

          -  Subject is currently receiving or has received systemic corticosteroids <14 days prior
             to starting study drugs. The following uses of corticosteroids are permitted: a short
             duration (<5 days) of systemic corticosteroidssingle doses, any duration of topical
             applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways
             diseases), eye drops or local injections (e.g., intra-articular).

          -  Subject is currently receiving warfarin or other coumarin-derived anticoagulant for
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight
             heparin (LMWH), novel oral anticoagulants (NOACs) or fondaparinux is allowed.

          -  In subjects with a diagnosis of cirrhosis, sSubjects with a Child-Pugh score B or C
             are excluded. Please see chart in the ManualDocuments/Info tab of the electronic data
             capture system (EDC) for Child-Pugh score calculation. If subject does not have
             diagnosed or suspected cirrhosis, the Child-Pugh score does not need to be calculated.

          -  Subjects taking herbal supplements (St. John's Wort, gingko balboa, etc.) must
             discontinue these supplements 14 days prior to study registration.

          -  Consumption of grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges
             or products containing the juice of each within 7 days prior to study registration.